Viveve Announces Regulatory Approval for Viveve System in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
146
Viveve Announces Regulatory Approval for Viveve System in Taiwan

ENGLEWOOD, CO --(Marketwired - October 10, 2017) - Viveve Medical, Inc. ( NASDAQ : VIVE ), a medical technology company focused on women's health and wellness, today announced that it has received regulatory approval to market the Viveve® System from the Taiwanese Food and Drug Administration (TFDA) for use in general surgical procedures for electrocoagulation and hemostasis.

"Regulatory approval for the Viveve System in Taiwan, one of the largest markets in Asia for advanced medical technologies, is a significant milestone in our strategic commercialization efforts to offer this 30-minute single-session treatment to clinicians and women in the Asia Pacific region," said Patricia Scheller, chief executive officer of Viveve. "We fully support our distribution partner for this market, Dynamic Medical Technologies, Inc., and their commitment to provide physicians and medical professionals with high-quality, clinically-proven products supported by exceptional marketing and training services."

Regulatory approvals and clearances for the Viveve System for treatment of vaginal laxity and/or improvement in sexual function indications have been received from more than 50 countries. In the United States, the Viveve System is currently cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis. Viveve is in the process of submitting an investigational device exemption (IDE) to the U.S Food and Drug Administration (FDA) to conduct a pivotal study on use of the device for improvement in sexual function in women.

About Viveve Viveve Medical, Inc. is a women's health and wellness company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the GENEVEVE™ treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) energy-based technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in one 30-minute in-office session. This treatment is indicated for vaginal laxity or improvement of sexual function in 54 countries around the world.

InControl Products by Viveve are FDA cleared medical devices that treat stress, urge, and mixed incontinence conditions and products to improve pelvic floor strength. Viveve exclusively distributes InControl Medical's products to healthcare providers in the United States. For more information visit Viveve's website at www.viveve.com .

Safe Harbor Statement All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov . Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc. Geneveve is a trademark of Viveve, Inc.

Investor Relations contacts: Sarah McCabe Stern Investor Relations, Inc. 1270 Avenue of the Americas, Suite 408 New York, NY 10020 (212) 362-1200 sarah@sternir.com Michael Miller Amato and Partners, LLC 90 Park Avenue, 17th Floor New York, NY 10016 (212) 430-0360 admin@amatoandpartners.com Media contact: Sara Zelkovic Berry & Company Public Relations (212) 253-8881 szelkovic@berrypr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 92

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 155

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 178

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 205

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 76

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 239

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Vivid Seats Simplifies Market Structure and Tax Obligations

Updated Category News Views 221

Vivid Seats Streamlines Corporate Structure Vivid Seats Inc. (NASDAQ: SEAT), a leading online ticket marketplace, has embarked on a transformative journey to simplify its organizational framework. In a strategic move, the company has announced its Corporate Simplification Agreement, aimed at redefining how it operates while enhancing its tax efficiency and overall...

Continue Reading
NLS Pharmaceuticals Soars After Major Merger Announcement

Updated Category News Views 330

NLS Pharmaceuticals Sees Positive Stock Movement NLS Pharmaceuticals Ltd. (NASDAQ: NLSP) is experiencing significant upward momentum in its stock prices following a crucial announcement regarding a proposed merger. The company has filed a Form F-4 registration statement with the Securities and Exchange Commission, signaling an essential step toward completing this merger....

Continue Reading
Orchestra BioMed Achieves Key Financial and Operational Progress

Updated Category News Views 84

Orchestra BioMed Reports on Financial Performance and Business Updates Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO), a pioneering biomedical innovation company, recently presented its robust financial results for Q3 2024, reflecting both significant fiscal health and promising advancements in medical technology. The company is focused on elevating patient care through...

Continue Reading
Nutex Health Inc. Investors Urged to Join Securities Class Action

Updated Category News Views 130

Investors of Nutex Health Inc. Face Opportunities Amid Allegations Investors holding shares in Nutex Health Inc. are currently presented with a remarkable opportunity in light of claims surrounding securities fraud involving the Company. Founded as a notable player in the healthcare sector, Nutex Health has recently come under scrutiny due to alleged misleading statements...

Continue Reading
Empowering Resilience in Education: Embracing Failure with LetMeFail

Updated Category News Views 182

Transforming Education: LetMeFail's Innovative Approach LetMeFail is an exciting new educational initiative aimed at transforming how students perceive and deal with failure. In today's culture, where perfection is often idolized, this program makes it clear that setbacks can serve as important stepping stones toward personal growth and resilience. Unpacking the Goals of...

Continue Reading